Imagion Biosystems Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

Feb 28

Here's Why We're Not Too Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Jan 06

CEO

Imagion Biosystems no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Proulx	Executive Chairman	9.3yrs	AU$409.30k	0.47% A$ 13.1k
Ward Detwiller	Chief Business Officer	no data	sin datos	sin datos
Melanie Leydin	Company Secretary	less than a year	sin datos	sin datos

0.4yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de IBX no se considera experimentado ( 0.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Proulx	Executive Chairman	9.3yrs	AU$409.30k	0.47% A$ 13.1k
David Ludvigson	Non Executive Director	7.3yrs	AU$46.56k	0.042% A$ 1.2k
Brett Mitchell	Non-Executive Director	no data	sin datos	1.53% A$ 42.5k
Michael Harsh	Non-Executive Director	7.3yrs	AU$46.56k	0.020% A$ 552.5
Mark Van Asten	Non Executive Director	7.5yrs	AU$41.35k	0.047% A$ 1.3k

7.3yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de IBX se considera experimentada (5.8 años de antigüedad promedio).

Imagion Biosystems Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Imagion Biosystems Limited Announces Departure of Isaac Bright as CEO

Imagion Biosystems Limited Approves Election of Isaac Bright as Director

Imagion Biosystems Limited Appoints Robert Proulx as Non-Executive Chairman

Recent updates

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Imagion Biosystems Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.35 loss in FY 2022)

Imagion Biosystems Limited Announces Departure of Isaac Bright as CEO

Imagion Biosystems Limited Approves Election of Isaac Bright as Director

New major risk - Market cap size

First half 2023 earnings released: AU$0.007 loss per share (vs AU$0.005 loss in 1H 2022)

New major risk - Financial position

New minor risk - Financial data availability

Imagion Biosystems Limited Appoints Robert Proulx as Non-Executive Chairman

New minor risk - Share price stability

Imagion Biosystems Limited Announces CEO Changes

New major risk - Market cap size

Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Imagion Biosystems Limited Reports Positive Clinical Data At Breast Cancer Symposium

No independent directors

Here's Why We're Watching Imagion Biosystems' (ASX:IBX) Cash Burn Situation

First half 2022 earnings released: AU$0.005 loss per share (vs AU$0.001 loss in 1H 2021)

No independent directors

Imagion Biosystems Limited, Annual General Meeting, May 25, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Imagion Biosystems Limited Announces First Patient Enrolled in the MagSense® HER2 Breast Cancer Phase I First-In-Human Study

We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

Imagion Biosystems Limited Receives CSIRO Grant for Prostate Cancer Project

Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

Full year 2020 earnings released: AU$0.007 loss per share (vs AU$0.01 loss in FY 2019)

New 90-day high: AU$0.21

New 90-day high: AU$0.21

Here's Why We're Not Too Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation

Imagion Biosystems Limited Provides First-In-Human Study Update - Study Open for Enrolment

Imagion Biosystems Limited Announces Change of Company Secretary

Imagion Biosystems Limited announced that it expects to receive AUD 6 million in funding

Imagion Biosystems Limited Appoints Geoff Hollis as CFO

Imagion Biosystems Announces HREC Approval for Phase I Study

First half earnings released

CEO

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad